Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call

Aug 03, 2015, 08:00 ET from Merrimack Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Aug. 3, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Second Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, August 10.   

The call will cover an update on Merrimack's progress as well as a summary of second quarter 2015 financials. A press release detailing the information to be discussed on the call will be issued the afternoon of Monday, August 10. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 97495685.

A listen-only webcast of the call will be available in the Investors section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. For more information, please visit Merrimack's website at www.merrimackpharma.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT:

Investor Contact: Geoffrey M. Grande, CFA Merrimack 617-441-7602 ggrande@merrimackpharma.com

Media Contact: Dana Robie Merrimack 617-441-7408 drobie@merrimackpharma.com

SOURCE Merrimack Pharmaceuticals, Inc.



RELATED LINKS

http://www.merrimackpharma.com